Taiko Pharmaceutical Co.,Ltd. (TYO:4574)
Japan · Delayed Price · Currency is JPY 296.00
+10.00 (3.50%)
At close: Mar 5, 2026
Taiko Pharmaceutical Revenue
In the year 2025, Taiko Pharmaceutical had annual revenue of 6.40B JPY with 1.67% growth. Taiko Pharmaceutical had revenue of 2.17B in the quarter ending December 31, 2025, with 26.56% growth.
Revenue
6.40B
Revenue Growth
+1.67%
P/S Ratio
2.33
Revenue / Employee
29.89M
Employees
214
Market Cap
14.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.40B | 105.00M | 1.67% |
| Dec 31, 2024 | 6.29B | 172.00M | 2.81% |
| Dec 31, 2023 | 6.12B | 1.08B | 21.43% |
| Dec 31, 2022 | 5.04B | -6.26B | -55.39% |
| Dec 31, 2021 | 11.30B | -11.16B | -49.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 66.38B |
| Fuso Pharmaceutical Industries,Ltd. | 62.17B |
| Nippon Chemiphar | 32.52B |
| Morishita Jintan | 12.87B |
| Mizuho Medy | 11.26B |
| Wakamoto Pharmaceutical | 9.43B |
| WDB coco | 4.98B |
| SymBio Pharmaceuticals | 1.31B |